Our internationally recognised publications give you access to the expertise of hundreds of the world’s leading scientists, experts and researchers.

Our unrivalled collection of publications spans evidence-based clinical knowledge, research and regulatory information. The extensive breadth of content on MedicinesComplete supports your decision making, from research to the point of care and provides you with the world’s most trusted resources.

We’re excited to announce the launch of two new resources: Martindale’s ADR Checker, a quick and easy tool to support you when managing patients with adverse drug reactions, and the Palliative Care Formulary, the expert source of drug information in palliative and hospice care.

Subscribe Publication Updates

Publication Updates

12 Oct
British National Formulary logo
British National Formulary October 2021 Update

This update contains 9 significant changes, 7 new monographs, and 1 deleted preparation.

Significant Changes:
• COVID-19 vaccine: updated guidance in-line with Public Health England recommendations.

• Dapagliflozin: update to advice on use in renal impairment, including new indication for chronic kidney disease.

• Diabetic hyperglycaemic emergencies: updated guidance.

• Diabetic Ketoacidosis: title changed to Diabetic hyperglycaemic emergencies.

• Immunisation schedule: updated National flu immunisation programme in-line with Public Health England recommendations.

• Influenza vaccine: updated guidance in-line with Public Health England recommendations.

• Remdesivir: update to treatment duration.

• Tofacitinib (Xeljanz®): increased risk of major adverse cardiovascular events and malignancies with use of tofacitinib relative to TNF-alpha inhibitors [MHRA/CHM advice].

• Trientine dihydrochloride: name change to trientine, and update to dosing for Wilson’s disease.

New Monographs:
Adakveo® [crizanlizumab].

Adtralza® [tralokinumab].

Besremi® [ropeginterferon alfa-2b].

Bijuve® [estradiol with progesterone].

Byfavo® [remimazolam].

Pemazyre® [pemigatinib].

Verquvo® [vericiguat].

Deleted Preparations: Mysodelle® [misoprostol].

For further details on changes in the BNF click on
https://www.medicinescomplete.com/#/content/bnf/PHP107699?hspl=changes

12 Oct
Palliative Care Formulary October 2021 Update

This update contains 6 revised monographs.

The following monographs have been fully revised: Drug names; Opioid antagonists (therapeutic target within the CNS); Quick Clinical Guide: Reversal of opioid-induced respiratory depression.

The following monographs have undergone minor revision: Ferrous sulfate; Metronidazole; Prescribing for children.

12 Oct
Herbal Medicines logo
Herbal Medicines October 2021 UPDATE

Calendula and Raspberry have been revised, and Agnus Castus, Aloe Vera, Celery, Evening Primrose, Fucus, Garlic, Green Tea, Pokeroot and Valerian have been selectively revised. Pharmacopoeial, preparations, and manufacturers’ information have also been updated.

Revised monographs: Calendula, Raspberry.

Selective revisions: Agnus Castus, Aloe Vera, Celery, Evening Primrose, Fucus, Garlic, Green Tea, Pokeroot, Valerian.

Minor updates: USP-NF information has been globally updated.

12 Oct
Clarity’s Diagnosis and Treatment Guidance October 2021 Update

This update contains 7 significant changes, and 3 minor changes.

Significant changes:
• Sickle cell disease — reviewed. A literature search was conducted in July 2021 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic.

• Chest pain — reviewed. A literature search was conducted in May 2021 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. No major changes to the recommendations have been made.

• Temporomandibular disorders (TMJs) — reviewed. A literature search was conducted in July 2021 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic.

• Pruritus ani — reviewed. A literature search was conducted in July 2021 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. Minor changes to clinical recommendations have been made.

• Bunions — reviewed. A literature search was conducted in July 2021 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials (RCTs) published since the last revision of the topic. The section on Assessment has been moved to the Diagnosis section to improve clarity and navigation. An additional section on Surgical management has been added to the Management section. The basis for recommendation sections have been updated with current evidence in the literature. No major changes to clinical recommendations have been made.

• Breast pain – cyclical — reviewed. A literature search was conducted in June 2021 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. No major changes to recommendations have been made. A new section on the differential diagnosis of breast pain has been added.

• Constipation — minor update. Broken links to two external resources have been updated.

Minor changes:
• Heart failure – chronic — minor update. The advice to add iron studies as part of the assessment of a person with heart failure and to manage comorbidity of hypertension was added based on the European Society for Cardiology guidelines for the diagnosis and treatment of acute and chronic heart failure.

• Angio-oedema and anaphylaxis — minor update. The topic has been updated to align with the Resuscitation Council UK guideline Emergency treatment of anaphylaxis. Guidelines for healthcare providers [Resuscitation Council UK, 2021]. Recommendations to routinely administer IV or IM chlorphenamine and hydrocortisone have been removed from this topic.

• Smoking cessation — minor update. History of epilepsy added to the cautions section for nicotine replacement therapy in line with updated manufacturer’s SPC.

12 Oct
AHFS Drug Information logo
AHFS October 2021 Update

This update contains 6 new monographs, 27 revised monographs, and 3 discontinued monographs.

New monographs: Odevixibat; Belumosudil; Fexinidazole; Anifrolumab; Avalglucosidase Alfa; Belzutifan

Revised monographs: Bendamustine; Tofacitinib; Trabectedin; Trifluridine and Tipiracil; Mepolizumab; Opicapone; Casirivimab and Imdevimab; COVID-19 Vaccine (Pfizer-BioNTech); COVID-19 Vaccine (Moderna); Bamlanivimab and Etesevimab; Fluorides; Dexamethasone; Hydrocortisone; methylPREDNISolone; predniSONE; Antituberculosis Agents General Statement; Corticosteroids General Statement; Erythromycins General Statement; Amoxicillin/Clavulanate; Aminopenicillins General Statement; Natural Penicillins General Statement; Penicillinase-Resistant Penicillins General Statement; Buprenorphine; Ritonavir; Antiretroviral Agents General Statement; Rifapentine; Efavirenz

Discontinued monographs: Capreomycin; Didanosine; Stavudine

12 Oct
Stockley's Interactions Checker_logo
Stockley’s Interactions Checker October 2021 Update

New and updated interactions now available

For October, 369 new interactions have been added, and 64 existing interactions have been updated.

View more